| Mrs Freddy G Tisdale, MA CCCSLP | |
|
255 W Florida St, Suite 200 Jefferson Speech & Language Center Of St Tamm, Mandeville, LA 70448 | |
| (985) 626-8403 | |
| (985) 727-9871 |
| Full Name | Mrs Freddy G Tisdale |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 255 W Florida St, Mandeville, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023109808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 12008332 (Louisiana) | Primary |
| 235Z00000X | Speech-language Pathologist | 4135 (Louisiana) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Freddy G Tisdale, MA CCCSLP 255 W Florida St, Suite 200 Jefferson Speech & Language Center Of St Tamm, Mandeville, LA 70448 Ph: (985) 626-8403 | Mrs Freddy G Tisdale, MA CCCSLP 255 W Florida St, Suite 200 Jefferson Speech & Language Center Of St Tamm, Mandeville, LA 70448 Ph: (985) 626-8403 |
News Archive
Two new studies raise enough questions about a possible link between childhood cancer and light therapy for newborn jaundice that clinicians should exercise caution in prescribing the treatment for infants whose jaundice is likely to resolve on its own, a pediatric oncologist from Dana-Farber/Boston Children's Cancer and Blood Disorders Center argues in an editorial published today by the journal Pediatrics.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
The University of California, San Diego Library has become the official repository for the papers of Jonas Salk, noted physician, virologist, and humanitarian, best known for his development of the world's first successful vaccine for the prevention of polio.
ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
› Verified 2 days ago
Gretchen Smith Bourgeois, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1011 N Causeway Blvd Ste 25, Mandeville, LA 70471 Phone: 985-626-8403 | |
Tara Grissom, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1011 N Causeway Blvd Ste 25, Mandeville, LA 70471 Phone: 985-626-8403 | |
Talk2me Speech Therapy Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1305 W Causeway Approach Ste A, Mandeville, LA 70471 Phone: 985-640-3988 Fax: 985-228-6316 | |
Melissa G Ogden, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1405 Highway 1088, Mandeville, LA 70448 Phone: 985-626-8238 | |
Nancy Rhodes, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Hurricane Aly, Mandeville, LA 70471 Phone: 985-875-7501 | |
Mrs. Shari Seal Turni, M.ED. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 519 Massena St, Mandeville, LA 70448 Phone: 859-626-3950 Fax: 985-674-0886 |